CN118510762A - 用作ampk激活剂的噻二唑酮衍生物 - Google Patents

用作ampk激活剂的噻二唑酮衍生物 Download PDF

Info

Publication number
CN118510762A
CN118510762A CN202280073480.7A CN202280073480A CN118510762A CN 118510762 A CN118510762 A CN 118510762A CN 202280073480 A CN202280073480 A CN 202280073480A CN 118510762 A CN118510762 A CN 118510762A
Authority
CN
China
Prior art keywords
compound
methyl
oxo
chlorophenyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280073480.7A
Other languages
English (en)
Chinese (zh)
Inventor
T·埃德伦德
J·韦斯特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagineng Co
Original Assignee
Betagineng Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagineng Co filed Critical Betagineng Co
Publication of CN118510762A publication Critical patent/CN118510762A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
CN202280073480.7A 2021-09-02 2022-09-01 用作ampk激活剂的噻二唑酮衍生物 Pending CN118510762A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2112529.9A GB202112529D0 (en) 2021-09-02 2021-09-02 New compounds
GB2112529.9 2021-09-02
PCT/GB2022/052234 WO2023031609A1 (en) 2021-09-02 2022-09-01 Thiadiazolone derivatives useful as ampk activator

Publications (1)

Publication Number Publication Date
CN118510762A true CN118510762A (zh) 2024-08-16

Family

ID=78076730

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280073480.7A Pending CN118510762A (zh) 2021-09-02 2022-09-01 用作ampk激活剂的噻二唑酮衍生物

Country Status (11)

Country Link
US (1) US20250136563A1 (enExample)
EP (1) EP4396171A1 (enExample)
JP (1) JP2024535745A (enExample)
KR (1) KR20240055039A (enExample)
CN (1) CN118510762A (enExample)
AU (1) AU2022336441A1 (enExample)
CA (1) CA3230307A1 (enExample)
GB (1) GB202112529D0 (enExample)
IL (1) IL310871A (enExample)
MX (1) MX2024002674A (enExample)
WO (1) WO2023031609A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200720264A (en) * 2005-04-25 2007-06-01 Lundbeck & Co As H Pro-drugs of n-thiazol-2-yl-benzamide derivatives
US20090156644A1 (en) * 2005-07-21 2009-06-18 Jacob Westman Use of thiazole derivatives and analogues in the treatment of cancer
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
JP2013230986A (ja) * 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
KR101889993B1 (ko) * 2010-09-10 2018-08-20 시오노기세야쿠 가부시키가이샤 Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체
WO2013108026A1 (en) * 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
CN111848579B (zh) * 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds

Also Published As

Publication number Publication date
US20250136563A1 (en) 2025-05-01
IL310871A (en) 2024-04-01
EP4396171A1 (en) 2024-07-10
CA3230307A1 (en) 2023-03-09
AU2022336441A1 (en) 2024-03-07
WO2023031609A1 (en) 2023-03-09
JP2024535745A (ja) 2024-10-02
MX2024002674A (es) 2024-03-19
KR20240055039A (ko) 2024-04-26
GB202112529D0 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
US20250136563A1 (en) Thiadiazolone derivatives useful as ampk activator
CN1918119B (zh) 双环酯类衍生物
JP2004534815A (ja) 抗糖尿病薬としての３−フルオロ−ピロリジン
JP5248331B2 (ja) 重水素化カテコールアミン誘導体およびその化合物を含む薬剤
CN101279955B (zh) 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
JP2002363157A (ja) 新規α−アミノ酸化合物、その調製方法及びそれを含有する医薬組成物
CN107531649B (zh) 含二芳基甲烷结构的羧酸类urat1抑制剂、制备方法及其用途
EP4222147B1 (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
US12391661B2 (en) Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
JP2010120851A (ja) 二量化シクロ誘導体
EP3445772A2 (en) Peptide-oligourea foldamer compounds and methods of their use
JP2009190971A (ja) ２−シアノピロリジン誘導体
CN111788196A (zh) 缩醛化合物及其治疗用途
WO2024089159A1 (en) Main protease inhibitors
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
JP2024506715A (ja) ソマトスタチンモジュレーターの結晶形態
FI83525C (fi) Foerfarande foer att framstaella en farmakologiskt vaerdefull 1-metyl-4,5-dihydro-orotylhistidyl-prolinamid.
CN112341390B (zh) 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
CN113620887A (zh) 一类sirt5蛋白抑制剂及其用途
HK40092998B (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
HK40092998A (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
RU2836443C1 (ru) Пероральные агонисты рецепторов glp
WO2024120448A1 (zh) 一种hdac抑制剂及其用途
JPS6133197A (ja) ジヒドロオロツト酸誘導体およびその製法
WO2023050037A1 (zh) 一种胞外亲环素抑制剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Sweden

Address after: Sweden

Applicant after: Tajinong Co.,Ltd.

Address before: Sweden

Applicant before: Betagineng Co.

Country or region before: Sweden

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination